A method of detecting an amine-based shale inhibitor in a wellbore servicing fluid (WSF) comprising contacting an aliquot of the WSF with an amine detector compound to form a detection solution; wherein the WSF comprises the amine-based shale inhibitor; and wherein the detection solution is characterized by at least one absorption peak wavelength in the range of from about 380 nm to about 760 nm; detecting an absorption intensity for the detection solution at a wavelength within about +20% of the at least one absorption peak wavelength; comparing the absorption intensity of the detection solution at the wavelength within about +20% of the at least one absorption peak wavelength with a target absorption intensity of the amine-based shale inhibitor to determine the amount of amine-based shale inhibitor in the WSF; and comparing the amount of amine-based shale inhibitor in the WSF with a target amount of the amine-based shale inhibitor.

A method of detecting an amine-based shale inhibitor in a wellbore servicing fluid (WSF) comprising contacting an aliquot of the WSF with an amine detector compound to form a detection solution; wherein the WSF comprises the amine-based shale inhibitor; and wherein the detection solution is characterized by at least one absorption peak wavelength in the range of from about 380 nm to about 760 nm; detecting an absorption intensity for the detection solution at a wavelength within about +20% of the at least one absorption peak wavelength; comparing the absorption intensity of the detection solution at the wavelength within about +20% of the at least one absorption peak wavelength with a target absorption intensity of the amine-based shale inhibitor to determine the amount of amine-based shale inhibitor in the WSF; and comparing the amount of amine-based shale inhibitor in the WSF with a target amount of the amine-based shale inhibitor.

Provided are compounds of formulae provided herein. The compounds may include pathway-preferential estrogens (PaPEs) derivatives with tissue-selective activities. Also provided are pharmaceutical compositions comprising the compounds, as well as methods of treating a disease or condition including administering the compounds. The disease or condition may include postmenopausal symptoms, cardiovascular disease, stroke, vascular disease, bone disease, metabolic disease, arthritis, osteoporosis, obesity, vasomotor/hot flush, cognitive decline, cancer including breast cancer.

Provided are compounds of formulae provided herein. The compounds may include pathway-preferential estrogens (PaPEs) derivatives with tissue-selective activities. Also provided are pharmaceutical compositions comprising the compounds, as well as methods of treating a disease or condition including administering the compounds. The disease or condition may include postmenopausal symptoms, cardiovascular disease, stroke, vascular disease, bone disease, metabolic disease, arthritis, osteoporosis, obesity, vasomotor/hot flush, cognitive decline, cancer including breast cancer.

There is described a method of preparing a compound of formula I, and optical isomers thereof; in which R.sup.1 is hydrogen or a protecting group; said method comprising oxidizing verbenone and optical isomers thereof. ##STR00001##

There is described a method of preparing a compound of formula I, and optical isomers thereof; in which R.sup.1 is hydrogen or a protecting group; said method comprising oxidizing verbenone and optical isomers thereof. ##STR00001##

There is described a method of preparing a compound of formula I, and optical isomers thereof; in which R.sup.1 is hydrogen or a protecting group; said method comprising oxidizing verbenone and optical isomers thereof. ##STR00001##

The present invention relates to a new process for the synthesis of 17-hydroxy-des-A-androst-9,10-en-5-one, the compound of the following formula (1), which can be used as an intermediate in the synthesis of retroprogesterones.

The present invention relates to a new process for the synthesis of 17-hydroxy-des-A-androst-9,10-en-5-one, the compound of the following formula (1), which can be used as an intermediate in the synthesis of retroprogesterones.

Provided are compounds of formulae provided herein. The compounds may include pathway-preferential estrogens (PaPEs) derivatives with tissue-selective activities. Also provided are pharmaceutical compositions comprising the compounds, as well as methods of treating a disease or condition including administering the compounds. The disease or condition may include postmenopausal symptoms, cardiovascular disease, stroke, vascular disease, bone disease, metabolic disease, arthritis, osteoporosis, obesity, vasomotor/hot flush, cognitive decline, cancer including breast cancer.